Tirzepatide in the treatment of type 2 diabetes mellitus:a rapid health technology assessment
10.12173/j.issn.1005-0698.202504004
- VernacularTitle:替尔泊肽治疗2型糖尿病的快速卫生技术评估
- Author:
Yunxuan ZHANG
1
;
Haifeng ZHOU
1
;
Ningzhou GAO
1
;
Jianbo WU
1
;
Cheng QIAN
1
;
Min ZHANG
1
;
Han GUO
1
;
Zhongjuan SONG
1
;
Xiaoyan LIU
1
Author Information
1. 复旦大学附属华东医院药剂科(上海 200040)
- Publication Type:Journal Article
- Keywords:
Tirzepatide;
Type 2 diabetes mellitus;
Rapid health technology assessment;
Efficacy;
Safety;
Cost-effectiveness
- From:
Chinese Journal of Pharmacoepidemiology
2025;34(9):1057-1065
- CountryChina
- Language:Chinese
-
Abstract:
Objective To conduct a rapid health technology assessment(rHTA)of the efficacy,safety,and cost-effectiveness of tirzepatide for the treatment of type 2 diabetes mellitus(T2DM),and to provide evidence for clinical medication.Methods PubMed,Web of Science,Embase,Cochrane Library,WanFang Data,CNKI databases,and health technology assessment(HTA)websites were searched to collect systematic reviews/Meta-analysis,pharmacoecomic literature and HTA reports of tirzepatide in the treatment of T2DM from inception to February 28,2025.Two researchers independently conducted literature screening,data extraction,and quality assessment,and then summarized and analyzed the results.Results A total of 13 articles were included,comprising 2 HTA reports,8 systematic reviews/Meta-analyses,and 3 pharmacoeconomic studies.In terms of efficacy,tirzepatide outperformed placebo or other antidiabetic drugs in reducing glycated hemoglobin(HbA1c),increasing the rate of HbA1c＜7％,lowering blood glucose,and reducing weight.The antihyperglycemic and weight-loss effects of tirzepatide were dose-dependent,and it also had certain advantages in reducing the risk of cardiovascular events and renal composite endpoint events.Regarding safety,the incidence of gastrointestinal adverse events in the tirzepatide group was higher than that in the placebo group and the insulin group,mainly manifested as diarrhea,nausea,and vomiting.However,it did not increase the risk of serious gastrointestinal adverse events,nor did it increase the risk of hypoglycemia and pancreatitis.In terms of cost-effectiveness,tirzepatide had cost-utility and cost-effectiveness advantages compared with semaglutide and other antidiabetic drugs.Conclusion Compared with other antidiabetic drugs,tirzepatide has better efficacy,safety,and cost-effectiveness in the treatment of T2DM.
